Rite Aid announces flu clinics at more than one thousand stores
CAMP HILL, Pa. Nearly 1,300 Rite Aid pharmacies will offer a one-day flu clinic on October 21, 22 or 23, the drug chain announced Monday. Flu shots are available at no cost for patients with Medicare Part B health coverage and $30 for all other patients; pneumonia shots are available for $45.
“Rite Aid is committed to offering our patients programs and services to help them live healthier lives,” stated Robert Thompson, senior vice president, pharmacy operations for Rite Aid. “By offering flu and pneumonia shots we hope to help decrease the number of illnesses and keep our communities healthy this coming flu season.”
A list of participating locations and the date and time of each clinic is available on the Rite Aid website, www.riteaid.com, or by calling 1-866-751-1494.
More than 1,200 Rite Aid pharmacists throughout the country are specially trained to offer vaccinations throughout the year for patients age 11 or older (patients must be age 18 or older in some states).
Rite Aid reports cash dividend payout for preferred stock
CAMP HILL, Pa. Rite Aid on Monday declared a cash dividend of $0.4049 per share on its 5.5 percent Series I Mandatory Convertible Preferred Stock for the period commencing on Aug. 1, 2008 through Nov. 16, 2008.
The dividend is payable on Nov. 17, 2008 to shareholders of record as of Oct. 15, 2008, the company stated.
Deciphera, Lilly partner to test compounds in treatment of cancer
INDIANAPOLIS Eli Lilly and Deciphera Pharmaceuticals said Friday they would collaborate to investigate a group of Deciphera compounds as a potential cancer treatment.
The companies said they would investigate Deciphera’s preclinical B-Raf kinase inhibitors as cancer treatments, combining Deciphera’s drug-discovery resources and Lilly’s drug discovery, development and commercialization resources.
“This collaboration is further evidence of Lilly’s ongoing commitment to oncology research,” Lilly vice president for discovery research and clinical investigation Dr. William Chin said. “We look forward to working with Deciphera to leverage their B-Raf kinase inhibitor program, with the ultimate goal of developing promising drug candidates for cancer patients.”
As part of the deal, Lilly will obtain exclusive worldwide rights to any products developed as part of the collaboration, while Deciphera will receive an upfront payment and research funding, as well as up to $130 million in development, regulatory and sales milestone payments.